ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD24 Monoclonal Antibody PHST001

Its studies are led by Pheast Therapeutics.

Furthest: phase 1, since Feb 10, 20251 company-led study, 1 open or runningNext primary completion: Apr 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pheast Therapeutics11 open or runningphase 1since Feb 10, 2025Feb 10, 2025Apr 2029phase 1 · NCT06840886

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06840886 · 426 planned · United States

Ahead

  1. Apr 2029Primary completion: phase 1 study in Ovarian NeoplasmsNCT06840886

TargetBeta

CD24 →read by rule
“A humanized monoclonal antibody directed against the cell surface protein cluster of differentiation 24 (CD24), ”NCIt, by rule

Other programs on CD24

ProgramCompanyFurthest phaseStudies
Anti-CD24/Anti-CD3 Bispecific Antibody ONC-783ruleoncoc4-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06840886Ovarian Neoplasms · United States1RecruitingApr 2029426

How it is read

Names in the registry

  • “PHST001”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.